The OncLive Immunotherapy in Melanoma condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in melanoma and other skin cancers. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment.
April 22nd 2024
SCIB1 plus nivolumab and ipilimumab elicited responses in patients with advanced, unresectable melanoma.
Real-World Data Show Improved Survival With Adjuvant Immunotherapy in Melanoma
The use of adjuvant immunotherapy in patients with resected stage IIIC melanoma resulted in improved survival benefit, according to real-world data from an early analysis of the National Cancer Database.
Longer Follow-Up for Cemiplimab Confirms Superior Efficacy Over Other Regimens for CSCC
May 31st 2020In the phase 2 trial EMPOWER-CSCC-1, up to 3 years of follow-up showed continued response rates, and a clinically meaningful survival and duration of response for cemiplimab-rwlc in patients with advanced cutaneous squamous cell carcinoma.
AMG 510 Shows Clinical Activity in Advanced KRAS G12C-Mutant Solid Tumors
May 30th 2020AMG 510, a novel KRAS G12C inhibitor, demonstrated early evidence of a consistent safety profile and anticancer activity across a range of advanced KRAS G12C-mutant solid tumors other than non–small cell lung cancer and colorectal cancer.
Neoadjuvant Nivolumab Shows Strong Clinical Activity in Merkel Cell Carcinoma
May 4th 2020Nivolumab, when administered approximately 4 weeks prior to surgery in patients with Merkel cell carcinoma, was found to be tolerable and to induce pathological complete responses and radiographic tumor regressions.
Atezolizumab Plus Vemurafenib/Cobimetinib Impresses in BRAF V600+ Melanoma
Treatment with atezolizumab in combination with vemurafenib and cobimetinib was found to significantly improve progression-free survival and produce durable responses versus vemurafenib and cobimetinib alone in treatment-naïve patients with BRAF V600–mutant advanced melanoma.
John Theurer Cancer Center Evaluating Personalized Cancer Vaccine in High-Risk Melanoma
March 4th 2020An ongoing clinical trial will assess whether the adjuvant combination of the personalized cancer vaccine mRNA-4157 and pembrolizumab improves recurrence-free survival compared with pembrolizumab alone in patients with complete resection of cutaneous melanoma and a high-risk of recurrence.